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Introduction: The most common cause of congenital adrenal hyperplasia (CAH) is 21-
hydroxylase deficiency (21-OHD) caused by alterations in CYP21A2 gene. The clinical 
phenotypes of this autosomal recessive disease are classified as classic (saltwasting and simple 
virilizing) and non-classic forms of CAH. The severity of the disease is directly related with the 
impairment of the 21-OH enzymatic activity. Genetic testing can confirm the disease and is 
crucial for familial studies and genetic counseling. Aim: The aim of this work was to perform the 
clinical and molecular characterization of the patients observed at the Hospital Pediátrico de 
Coimbra (Portugal) with the clinical suspecion of CAH.  
Methods: Retrospective analysis of patient medical records of all cases observed in our hospital 
with suspicion of CAH and detailed literature comparison. CYP21A2 molecular analysis had 
been performed in 81 unrelated Portuguese patients (51 female, 30 males) with clinical and 
endocrine laboratorial findings suggestive of CAH, using mini-sequencing, restriction enzyme 
digestion, Sanger sequencing or/and multiplex ligation-dependent probe amplification (MLPA).  
Results: CYP21A2 variants were identified in 74/81 (91%) of the patients. Homozygosity for 
CYP21A2 was found in 39.2% (29/74) of the patients while 55.4% (41/74) were compound 
heterozygous and, in 5.4% of the cases (4/74), only one pathogenic variant was identified. The 
most frequent alterations were p.Val281Leu, g.655A/C>G (splicing variant) and p.Ile172Asn, 
that account for more than 50% of the alleles of this patient's cohort. All variants were already 
described except a novel missense variant identified in a salt-wasting patient, 
g.1173T>C(p.Trp201Arg). The rare variant p.Gly424Ser which was detected in one patient had 
been previously associated with a possible founder effect in Brazil and the splicing variant 
g.391G>A, only described in the Portuguese population.  
Conclusion: Our study provides a detailed clinical and molecular characterization of a large 
cohort of CAH Portuguese patients. The overall concordance between the clinical phenotype 
and the inferred phenotype (based on genotype) was 90%. 
 
 
 
 
  
